Sodium Oxybate

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Binge Eating Disorder

Conditions

Binge Eating Disorder

Trial Timeline

Aug 1, 2007 → Apr 1, 2011

NCT ID

NCT00514995

About Sodium Oxybate

Sodium Oxybate is a phase 2/3 stage product being developed by Jazz Pharmaceuticals for Binge Eating Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00514995. Target conditions include Binge Eating Disorder.

What happened to similar drugs?

2 of 8 similar drugs in Binge Eating Disorder were approved

Approved (2) Terminated (1) Active (5)

✅Duloxetine + PlaceboEli LillyApproved

✅Solriamfetol + PlaceboJazz PharmaceuticalsApproved

🔄Zonegran + sugar pillEisaiPhase 3

🔄dasotraline 4mg + dasotraline 6mg + PlaceboSumitomo PharmaPhase 3

🔄DasotralineSumitomo PharmaPhase 3

❌Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + PlaceboNovo NordiskPhase 3

🔄Solriamfetol 75mg, 150 mg, or 300 mgAxsome TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04006925	Approved	Completed	Sep 10, 2019	Feb 1, 2022	REM Sleep Behavior Disorder
NCT00931164	Phase 1/2	Completed	Aug 1, 2009	Sep 1, 2011	Alternating Hemiplegia of Childhood
NCT00594256	Phase 2	Completed	May 1, 2008	Apr 1, 2009	Schizophrenia
NCT00514995	Phase 2/3	Completed	Aug 1, 2007	Apr 1, 2011	Binge Eating Disorder
NCT00506974	Approved	Completed	May 1, 2007	Jun 1, 2008	Sleep
NCT00641186	Phase 2	Completed	Sep 1, 2004	Nov 1, 2008	Parkinson Disease

Competing Products

11 competing products in Binge Eating Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + Placebo	Eli Lilly	Approved	43
Zonegran + sugar pill	Eisai	Phase 3	40
Dasotraline + Placebo	Sumitomo Pharma	Phase 2/3	38
dasotraline 4mg + dasotraline 6mg + Placebo	Sumitomo Pharma	Phase 3	40
Dasotraline	Sumitomo Pharma	Phase 3	40
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo	Novo Nordisk	Phase 3	32
Solriamfetol + Placebo	Jazz Pharmaceuticals	Approved	36
Solriamfetol 75mg, 150 mg, or 300 mg	Axsome Therapeutics	Phase 3	44
Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo	Axsome Therapeutics	Phase 3	44
RDC-0313 (ALKS 33) + Placebo	Alkermes	Phase 2	32
ACT-539313 + Placebo	Idorsia	Phase 2	29